Mengis Capital Management’s Gilead Sciences GILD Stock Holding History

Mengis Capital Management’s Portfolio GILD Stock Details GILD Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-3,646	Closed	-$247K	–	119
2017 Q1	$247K	Buy	3,646 +125	+4%	+$8.79K	0.18%	107
2016 Q4	$252K	Sell	3,521 -3,914	-53%	-$291K	0.2%	100
2016 Q3	$588K	Sell	7,435 -50	-0.7%	-$4.06K	0.49%	62
2016 Q2	$624K	Buy	7,485 +475	+7%	+$42.2K	0.55%	60
2016 Q1	$643K	Sell	7,010 -800	-10%	-$72.1K	0.59%	57
2015 Q4	$790K	Buy	7,810 +1,110	+17%	+$115K	0.69%	44
2015 Q3	$657K	Buy	6,700 +1,625	+32%	+$180K	0.61%	53
2015 Q2	$594K	Buy	5,075 +2,300	+83%	+$251K	0.5%	67
2015 Q1	$272K	Buy	+2,775	New	+$282K	0.24%	91

Other funds holding GILD

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Bank of New York Mellon New York $544B AUM 28.31% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Parnassus Investments San Francisco, California $34.1B AUM 20.22% 1-Year Est. Return

Capital Research Global Investors Los Angeles, California $645B AUM 30.41% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Northern Trust Chicago, Illinois $757B AUM 28.64% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Mengis Capital Management's GILD Position: Q2 2017 in Review

Mengis Capital Management sold out of Gilead Sciences (GILD) in Q2 2017, closing a stake of 3,646 shares — an estimated $247K sold.

Mengis Capital Management first reported a position in GILD in Q1 2015 and held it in 9 quarters. The position peaked at $790K in Q4 2015. 1,519 funds tracked by Wall St. Rank hold GILD as of Q2 2017.

Mengis Capital Management reported no remaining Gilead Sciences position as of Q2 2017 after selling out during the quarter.
Mengis Capital Management sold 3,646 Gilead Sciences shares in Q2 2017, an estimated $247K.
Mengis Capital Management first reported a position in Gilead Sciences in Q1 2015 and held it in 9 quarters.
Mengis Capital Management's Gilead Sciences position peaked at $790K in Q4 2015.
1,519 funds tracked by Wall St. Rank held Gilead Sciences as of Q2 2017.

Based on Mengis Capital Management's 13F filing for Q2 2017, filed 1 Aug 2017.